- $209.29m
- $144.98m
- $83.79m
- 45
- 28
- 87
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.44 | ||
| Price to Tang. Book | 2.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.69% | ||
| Return on Equity | -55.25% | ||
| Operating Margin | -68.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 32.73 | 48.42 | 53.66 | 68.67 | 83.79 | 96.91 | 115.2 | 20.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Directors
- Dana Mead NEC (61)
- Glendon French PRE (59)
- Derrick Sung CFO (48)
- David Lehman GCN (60)
- Geoffrey Rose OTH (47)
- Alissa Lynch DRC
- Michael Matly DRC (39)
- Tiffany Sullivan DRC
- Thomas Burns IND (60)
- Richard Ferrari IND (67)
- Daniel Florin IND (57)
- Georgia Garinois- Melenikiotou IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 4th, 2013
- Public Since
- October 1st, 2020
- No. of Shareholders
- 126
- No. of Employees
- 291
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 40,247,480
- Address
- 700 Chesapeake Dr, REDWOOD CITY, 94063
- Web
- https://pulmonx.com/
- Phone
- +1 6509342600
- Contact
- Brian Johnston
- Auditors
- BDO USA, LLP
Upcoming Events for LUNG
Q1 2025 Pulmonx Corp Earnings Call
Pulmonx Corp Annual Shareholders Meeting
Pulmonx Corp Annual Shareholders Meeting
Q2 2025 Pulmonx Corp Earnings Release
Similar to LUNG
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Pulmonx share price?
As of Today at 22:46 UTC, shares in Pulmonx are trading at $5.20. This share price information is delayed by 15 minutes.
How has the Pulmonx share price performed this year?
Shares in Pulmonx last closed at $5.20 and the price had moved by -28.77% over the past 365 days. In terms of relative price strength the Pulmonx share price has underperformed the S&P500 Index by -34.25% over the past year.
What are the analyst and broker recommendations for Pulmonx?
The overall consensus recommendation for Pulmonx is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pulmonx dividend yield?
Pulmonx does not currently pay a dividend.
Does Pulmonx pay a dividend?
Pulmonx does not currently pay a dividend.
When does Pulmonx next pay dividends?
Pulmonx does not currently pay a dividend.
How do I buy Pulmonx shares?
To buy shares in Pulmonx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pulmonx?
As of the previous close price of $5.20, shares in Pulmonx had a market capitalisation of $209.29m.
Where are Pulmonx shares listed?
Here are the trading details for Pulmonx:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: LUNG
What kind of share is Pulmonx?
Based on an overall assessment of its quality, value and momentum Pulmonx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pulmonx share price forecast for 2025?
The analyst consensus target price for shares in Pulmonx is $12.36. That is 137.69% above the last closing price of $5.20.
Analysts covering Pulmonx currently have a consensus Earnings Per Share (EPS) forecast of -$1.55 for the next financial year.
Find out moreWhat is the trend in the Pulmonx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pulmonx. Over the past six months, its share price has underperformed the S&P500 Index by -9.11%.
As of the last closing price of $5.20, shares in Pulmonx were trading -24.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pulmonx PE Ratio?
The Pulmonx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pulmonx?
Pulmonx's management team is headed by:
- Dana Mead - NEC
- Glendon French - PRE
- Derrick Sung - CFO
- David Lehman - GCN
- Geoffrey Rose - OTH
- Alissa Lynch - DRC
- Michael Matly - DRC
- Tiffany Sullivan - DRC
- Thomas Burns - IND
- Richard Ferrari - IND
- Daniel Florin - IND
- Georgia Garinois- Melenikiotou - IND